HopeStage
Back to all studies
TerminatedNCT01813019

Effect of AFQ056 for people Diagnosed With OCD and Resistant to SSRI Treatment; Failed SSRI Over 12 Weeks at Appropriate Doses

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who could participate?

This study is for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
San Diego and 14 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateNovember 2013
Recruitment status
Terminated
Enrollment listed in the registry
50
Sponsor
Novartis Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Switzerland, Bulgaria, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01813019
Official title
Show the full official title

A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Recruitment & locations

Terminated

San Diego, United States · Watertown, United States · Brooklyn, United States

12 more locations
  • Burgas, Bulgaria
  • Pazardzhik, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Strakonice, Czechia
  • Berlin, Germany
  • Freiburg im Breisgau, Germany
  • München, Germany
  • Nuremberg, Germany
  • Ulm, Germany
  • Bern, Switzerland
  • Czechia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Novartis Pharmaceuticals.

Does this study involve medication?

Yes. The study involves medication, including AFQ056 and Placebo.

Who can participate?

This study is for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies